Global

‡ In these countries please contact our distributor

Smith & Nephew presents a fresh approach to challenging wounds by combining holistic patient assessment with T.I.M.E. and pioneering solutions at the 2018 EWMA Conference

9 May 2018

EWMA

Smith & Nephew (NYSE:SNN; LSE:SN), the global medical technology business, is proud to announce several recent launches to be showcased at the European Wound Management Association (EWMA) conference to be held in Krakow, Poland 9 – 11 May 2018.

“Wound care costs billions of pounds each year, and it is estimated that the prevalence of chronic wounds is growing at 12% per annum.1 When wounds don’t heal, costs spiral."1 said Paolo Di Vincenzo, Smith & Nephew’s SVP of Advanced Wound Management. “This is why we are proud to showcase a number of new products and programmes at this year’s EWMA, adding to our already established portfolio designed to help healthcare professionals further reduce the human and economic cost of wounds. Among these new introductions, we have worked in partnership with expert and experienced specialist wound care nurses and clinicians to develop a new unique and easy to implement plan-on-a-page (POP) support tool – based on T.I.M.E.2,3 The new POP tool is designed to aid clinicians in their routine decision-making around chronic wounds to help them improve daily practice consistently.”

Within the newly introduced POP tool, T.I.M.E. is part of a systematic and holistic evaluation of each patient at every wound assessment. T.I.M.E. was first developed by an international group of wound healing experts and provides a framework for a structured approach to wound bed preparation.2,3 The T stands for tissue non-viable, I for infection and/or inflammation, M for moisture imbalance and E for edge of wound non-advancing. The launch of the POP tool is supported by a symposium, A fresh approach to challenging wounds by combining T.I.M.E. with pioneering solutions, which takes place at 13.15 on Thursday 10th May.

Dr Caroline Dowsett, Clinical Nurse Specialist Tissue Viability East London NHS Foundation Trust London and Independent Nurse Consultant in Wound Care is presenting “T.I.M.E. to improve patient outcomes” at the conference: “This symposium offers us an opportunity to gain new insights into how to improve patient outcomes by using a structured approach to wound assessment and management – also known as T.I.M.E. Delegates at the conference should attend in order to update their knowledge and understanding of new treatment modalities that can benefit patients and the wider health economy.”

Delegates will additionally have the opportunity to discover Smith and Nephew’s latest pioneering new technologies, such as the MolecuLight i:XTM Wound Intelligence Device, PICO 7 Single Use Negative Pressure Wound Therapy, ALLEVYN LIFE Non-Bordered and ALLEVYN Gentle Border.

The full Smith & Nephew conference programme can be found at smith-nephew.com/ewma2018.

Enquiries

Media

Dave Snyder
+1 (978) 749-1440
Smith & Nephew plc

References

1. Guest JF, Vowden K, Vowden P. The health economic burden that acute and chronic wounds impose on an average clinical commissioning group/health board in the UK. JWC. 2017;26(6):292-303.
2. Schultz GS, Sibbald RG, Falanga V et al. Wound bed preparation: a systematic approach to wound management. Wound Rep Reg. 2003;11(Suppl. 1):S1-28.
3. Leaper DJ, Schultz G, Carville K, Fletcher J, Swanson T, Drake R. Extending the T.I.M.E. concept: what have we learned in the past 10 years? Int Wound J. 2012;9(Suppl. 2):1–19.

About Smith & Nephew

Smith & Nephew is a global medical technology business dedicated to supporting healthcare professionals in their daily efforts to improve the lives of their patients. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma & Extremities, Smith & Nephew has more than 15,000 employees and a presence in more than 100 countries. Annual sales in 2017 were almost $4.8 billion. Smith & Nephew is a member of the FTSE100 (LSE: SN, NYSE: SNN).

For more information about Smith & Nephew, please visit our corporate website www.smith-nephew.com, follow @SmithNephewplc on Twitter or visit SmithNephewplc on Facebook.com

To learn more about how we can help you get CLOSER TO ZERO™ delay in wound healing, please visit www.closertozero.com

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.

◊ Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.